rilpivirine + rifabutin

**Rilpivirine + rifabutin** refers to the co-administration of the antiretroviral drug rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for HIV-1 infection, with rifabutin, an antibiotic primarily used to treat mycobacterial infections such as tuberculosis. Rilpivirine acts by inhibiting the HIV-1 reverse transcriptase enzyme, preventing viral replication[4][8]. Rifabutin inhibits bacterial DNA-dependent RNA polymerase, suppressing RNA synthesis and leading to cell death, and acts as a moderate inducer of the cytochrome P450 3A4 (CYP3A4) enzyme[2]. Their combination is clinically significant because rifabutin, as a CYP3A4 inducer, can reduce rilpivirine plasma concentrations potentially requiring rilpivirine dose adjustments if used together[5][1].

Other names

rilpivirine + rifabutin